Inflammation plays a prominent role in
tumor growth. Anti-inflammatory drugs have therefore been proposed as anti-
cancer therapeutics. In this study, we determined the anti-angiogenic activity of a single dose of liposomal
prednisolone phosphate (PLP-L), by monitoring
tumor vascular function and viability over a period of one week. C57BL/6 mice were inoculated subcutaneously with B16F10
melanoma cells. Six animals were PLP-L-treated and six served as control.
Tumor tissue and vascular function were probed using MRI before and at three timepoints
after treatment. DCE-MRI was used to determine K(trans), v(e), time-to-peak, initial slope and the fraction of non-enhancing pixels, complemented with immunohistochemistry. The apparent diffusion coefficient (ADC), T(2) and
tumor size were assessed with MRI as well. PLP-L treatment resulted in smaller
tumors and caused a significant drop in K(trans) 48 h post-treatment, which was maintained until one week after
drug administration. However, this effect was not sufficient to significantly distinguish treated from non-treated animals. The
therapy did not affect
tumor tissue viability but did prevent the ADC decrease observed in the control group. No evidence for PLP-L-induced
tumor vessel normalization was found on histology. Treatment with PLP-L altered
tumor vascular function. This effect did not fully explain the
tumor growth inhibition, suggesting a broader spectrum of PLP-L activities.